Sterling Capital Management’s CytomX Therapeutics CTMX Stock Holding History
Bought
Maintained
Sold
Other funds holding CTMX
KCM
Sterling Capital Management's CTMX Position: Q3 2026 in Review
Sterling Capital Management increased its CytomX Therapeutics (CTMX) stake by 148% in Q3 2026, buying an estimated $9.7K and bringing the position to 4,888 shares worth $13.3K. The position accounts for ﹤0.01% of the portfolio, ranked #2383.
Sterling Capital Management first reported a position in CTMX in Q4 2017 and has held it in 5 quarters since. The position peaked at $1.08M in Q1 2018. 194 funds tracked by Wall St. Rank hold CTMX as of Q3 2026.
- Sterling Capital Management held 4,888 shares of CytomX Therapeutics worth $13.3K as of Q3 2026.
- Sterling Capital Management bought 2,919 CytomX Therapeutics shares in Q3 2026, an estimated $9.7K.
- CytomX Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #2383 holding.
- Sterling Capital Management first reported a position in CytomX Therapeutics in Q4 2017 and has held it in 5 quarters since.
- Sterling Capital Management's CytomX Therapeutics position peaked at $1.08M in Q1 2018.
- 194 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2026.
Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.